Compare KELYB & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | JANX |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.8M | 975.7M |
| IPO Year | 1994 | 2021 |
| Metric | KELYB | JANX |
|---|---|---|
| Price | $23.27 | $19.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 633.0 | ★ 748.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $5,355,600,000.00 | $10,000,000.00 |
| Revenue This Year | $0.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $155.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.38 | $12.12 |
| 52 Week High | $125.00 | $35.34 |
| Indicator | KELYB | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 71.63 |
| Support Level | $21.49 | $13.00 |
| Resistance Level | $24.78 | $35.34 |
| Average True Range (ATR) | 0.70 | 0.71 |
| MACD | -0.08 | 0.16 |
| Stochastic Oscillator | 68.54 | 90.42 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.